Publication | Open Access
Improvement in Disease Activity in Refractory Juvenile Dermatomyositis Following Abatacept Therapy
24
Citations
23
References
2023
Year
This open-label study demonstrated that abatacept may be beneficial for patients with treatment-refractory juvenile DM.
| Year | Citations | |
|---|---|---|
Page 1
Page 1